Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2023-10-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the signing of a "Strategic Cooperation Framework Agreement" with another company. It details the nature of the agreement, the parties involved, the scope and terms of cooperation, and the expected impact on the company's business. There are no financial statements, quarterly or annual results, or audit information presented. The document is not a report but an announcement of a strategic partnership agreement. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a regulatory filing about shareholding changes or management changes. The document is a formal announcement of a strategic cooperation agreement, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-10-17 Chinese
普洛药业股份有限公司关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about receiving a drug registration certificate from a regulatory authority (国家药品监督管理局). It details the drug's basic information, approval, and potential impact on the company. There is no financial data, no mention of financial results, no management discussion, no voting results, or any other report type. The document is a regulatory announcement about a product approval, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a regulatory filing informing the market about a material event related to the company's product approval. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short and it is not a report publication announcement or certification letter, so RNS fits best with high confidence.
2023-10-11 Chinese
关于在德国投资设立子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's investment in establishing a wholly-owned subsidiary in Germany. It details the investment amount, purpose, and potential risks, and states compliance with relevant securities regulations. The document is relatively short (1325 characters) and does not contain financial statements or detailed financial data. It is an announcement of a capital investment activity rather than a full financial report or detailed management discussion. Therefore, it fits best under Capital/Financing Update (CAP).
2023-10-09 Chinese
关于对下属公司担保的进展公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company (普洛药业股份有限公司) for its subsidiaries' borrowings. It includes specifics about guarantee contracts, amounts, counterparties, and board approvals. There is no indication that this is a financial report like an annual or interim report, nor is it a transcript, presentation, or remuneration report. It is a regulatory announcement about financing guarantees, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories and is a formal disclosure to the market.
2023-10-08 Chinese
关于产业投资基金对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普洛药业股份有限公司 regarding an external investment by its wholly-owned subsidiary in another company, including details of the investment agreement, parties involved, shareholding structure before and after the investment, and financial data of the target company. It does not contain comprehensive financial statements or detailed financial performance analysis of the reporting company itself. The document is a formal disclosure about a capital investment transaction, which fits the category of Capital/Financing Update (CAP). The document length is about 4913 characters, which is sufficient for a detailed announcement but not a full financial report. There is no indication that this is an annual or interim report, audit report, or earnings release. Therefore, the best classification is CAP with high confidence.
2023-09-26 Chinese
关于控股子公司浙江普洛康裕制药有限公司通过美国FDA现场审计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary passing a US FDA on-site inspection with no action indicated. It includes details about the inspection, the products involved, and the impact on the company. The document is short (876 characters) and serves as a regulatory announcement about compliance and inspection results rather than a full report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-09-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.